Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.07. | XVivo Q2 2025: Umsatzrückgang lässt Aktie einbrechen | 8 | Investing.com Deutsch | ||
11.07. | XVIVO Perfusion AB: Interim Report January-June 2025 | 184 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 11, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)A quarter showing a mixed pictureSecond quarter 2025 (Apr-Jun)• Net sales amounted to SEK 178.3 million... ► Artikel lesen | |
11.07. | Marktgegenwind bremst XVIVO: Organisches Wachstum im zweiten Quartal um 11 % rückläufig | 4 | Investing.com Deutsch | ||
11.07. | XVIVO Q2 2025 slides reveal -11% organic growth amid market headwinds | 2 | Investing.com | ||
XVIVO PERFUSION Aktie jetzt für 0€ handeln | |||||
10.07. | XVIVO Perfusion AB: Conference Call on Interim Report April-June 2025 | 256 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / July 10, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report April-June 2025. The... ► Artikel lesen | |
13.06. | XVIVO Perfusion AB: XVIVO Honored with 2025 SACC-USA Business Award for Life-Saving Innovation and Growth in the U.S. Market | 233 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / June 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Yesterday, XVIVO received the prestigious Swedish American Chamber of Commerce USA (SACC-USA)... ► Artikel lesen | |
29.04. | XVIVO Perfusion AB: XVIVO Presents 12-Month Follow-Up Results from European Multicenter Heart Transplantation Trial at ISHLT in Boston | 287 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 29, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - The 12-month follow-up results from XVIVO's European multicenter heart trial, NIHP2019, was presented... ► Artikel lesen | |
25.04. | Bulletin from Annual General Meeting in XVIVO Perfusion AB | 336 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / April 25, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following resolutions were passed at the Annual General Meeting (the "AGM") of XVIVO Perfusion... ► Artikel lesen | |
24.04. | XVIVO Perfusion AB: Interim Report January-March 2025 | 218 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 24, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)First quarter 2025 (Jan-Mar)Net sales increased to SEK 218.6 million (186.0), corresponding to growth... ► Artikel lesen | |
15.04. | XVIVO Perfusion AB: Conference Call on Interim Report January-March 2025 | 358 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 15, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Invitation to attend XVIVO's conference call regarding the interim report January-March 2025.... ► Artikel lesen | |
02.04. | XVIVO Perfusion AB: Annual Report 2024 | 294 | ACCESS Newswire | GOTHENBURG, SE / ACCESS Newswire / April 2, 2025 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV)Today XVIVO Perfusion AB (publ) publish the Annual Report for 2024. The Annual Report is attached... ► Artikel lesen | |
20.03. | Notice to Attend the Annual General Meeting in XVIVO Perfusion AB | 316 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESS Newswire / March 20, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice... ► Artikel lesen | |
28.01. | XVIVO Perfusion AB: Year-End Report 2024 | 251 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / January 28, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Fourth quarter 2024 (October 1 - December 31)• Net sales amounted to SEK 227.6 million (155.7), corresponding... ► Artikel lesen | |
13.01. | XVIVO Perfusion AB: Conference Call on Year-End Report 2024 | 391 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / January 13, 2025 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Year-end Report... ► Artikel lesen | |
26.11.24 | XVIVO Perfusion AB: Enrollment Completed Five Months Early in the US Clinical Trial Evaluating XVIVOs Heart Preservation Technology | 407 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / November 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) XVIVO's innovative heart technology is currently under investigation in the US clinical trial "PRESERVE:... ► Artikel lesen | |
14.11.24 | XVIVO Perfusion AB: XVIVO Perfusion Appoints Lena Hagman as Deputy CEO | 287 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / November 14, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Board of Directors of XVIVO Perfusion AB (publ) ("XVIVO") has today appointed Lena Hagman... ► Artikel lesen | |
24.10.24 | XVIVO Perfusion AB: Interim Report January-September 2024 | 322 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / October 24, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)Third quarter 2024 (July 1 - September 30)• Net sales amounted to SEK 198.5 million (146.6), corresponding... ► Artikel lesen | |
10.10.24 | XVIVO Perfusion AB: Conference Call on Interim Report | 274 | ACCESS Newswire | GOTHENBURG, SE / ACCESSWIRE / October 10, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the interim report January-September... ► Artikel lesen | |
19.09.24 | XVIVO Perfusion AB: XVIVO to Acquire a Unique Communication Platform for the Transplant Process | 863 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) ("XVIVO" or "the Company") has entered into an agreement to acquire the transplant... ► Artikel lesen | |
06.09.24 | Nomination Committee of XVIVO Perfusion AB | 464 | ACCESS Newswire | GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)The following members have been appointed to XVIVO Perfusion's nomination committee for the 2025... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CARL ZEISS MEDITEC | 51,70 | +1,47 % | DEUTSCHE BANK RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Carl Zeiss Meditec vor der Quartalsbilanz mit einem Kursziel von 55 Euro auf "Hold" belassen. Der Medizintechnikhersteller... ► Artikel lesen | |
ECKERT & ZIEGLER | 67,30 | +0,07 % | EQS-News: Eckert & Ziegler SE: Ausbildungsqualität erneut ausgezeichnet | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): Sonstiges
Eckert & Ziegler: Ausbildungsqualität erneut ausgezeichnet
15.07.2025 / 14:00 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
INTUITIVE SURGICAL | 444,50 | -0,37 % | Intuitive Surgical, Inc.: Intuitive demonstrates telesurgery capabilities | SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, has today demonstrated... ► Artikel lesen | |
UNITEDHEALTH | 242,95 | -0,10 % | Bank-Bilanzen im Fokus - Bitcoin, Nel, United Health, ASML, Goldman Sachs, BoA, Johnson & Johnson | Die Wall Street beendete den gestrigen Handelstag uneinheitlich. Während Standardwerte kaum gefragt waren, sorgte erneut der Technologiebereich für Bewegung. Der Nasdaq 100 stieg zur Eröffnung auf ein... ► Artikel lesen | |
RHOEN-KLINIKUM | 12,000 | +0,84 % | Überregionales HFU-Zentrum für Herzinsuffizienz am RHÖN-KLINIKUM Campus Bad Neustadt erneut zertifiziert - Höchste Qualitätsstandards bestätigt | Bad Neustadt a.d. Saale (ots) - Nach eingehender Prüfung wurde die Klinik für Kardiologie I (Interventionelle Kardiologie und kardiale Bildgebung) am RHÖN-KLINIKUM Campus Bad Neustadt als Überregionales... ► Artikel lesen | |
HIMS & HERS HEALTH | 43,220 | -0,25 % | Hims & Hers nach Aus mit Novo Nordisk: "Erhöhtes Risiko von Rechtsstreitigkeiten" | Wie gewonnen, so zerronnen: Zunächst entfachte die umfangreiche Zusammenarbeit zwischen dem Telehealth-Unternehmen Hims & Hers und dem Biopharma-Riesen Novo Nordisk jede Menge Euphorie. Doch dann kam... ► Artikel lesen | |
BICO GROUP | 3,190 | +0,06 % | Toni Haberthür, CEO Bico / Hilding Anders Switzerland, im Interview | von Patrick Gunti Moneycab.com: Herr Haberthür, Bico steht «für ä tüüfä gsundä Schlaaf» und ist seit Jahrzehnten die bekannteste Marke der Schweiz im Bereich hochwertiger Schlaflösungen. Wie prägt die... ► Artikel lesen | |
M1 KLINIKEN | 14,380 | +0,14 % | Dividendenbekanntmachungen (17.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) CRANSWICK PLC GB0002318888 0,76 GBP 0,8762 EUR DIME COMMUNITY BANCSHARES INC US25432X1028 0,25 USD 0,2148 EUR EOG RESOURCES INC US26875P1012 0... ► Artikel lesen | |
BAXTER | 24,065 | +0,69 % | Minimale Kursveränderung bei Baxter-Aktie (23,9486 €) | Der Kurs der der Aktie von Baxter kommt kaum von der Stelle. Das Papier kostete zuletzt 27,83 US-Dollar. Einen geringen Wertverlust von 0,22 Prozent zeigt die Kurstafel für der Anteilsschein von Baxter... ► Artikel lesen | |
LIFEWARD | 0,730 | -1,82 % | Lifeward Ltd.: Administrative Law Judge Determines ReWalk Personal Exoskeleton is "Reasonable and Necessary" for Medicare Beneficiary | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, June 24, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
COOPER COMPANIES | 63,00 | +0,80 % | 6 Analysts Have This To Say About Cooper Companies | ||
JD HEALTH | 5,250 | 0,00 % | JD Health-Aktie mit Kursgewinnen (5,05 €) | An der Börse liegt der Anteilsschein von JD Health aktuell im Plus. Das Wertpapier kostete zuletzt 5,05 Euro. Für die JD Health-Aktie steht gegenwärtig ein Preisanstieg 1,41 Prozent zu Buche. Das Papier... ► Artikel lesen | |
SURGICAL SCIENCE SWEDEN | 13,180 | +0,53 % | Surgical Science Sweden AB: Interim report January - March 2025: Strong growth despite macroeconomic uncertainties | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 250.7 (188.2) million, an increase of 33 percent compared with the corresponding period in the preceding year. SEK 18.3 million was acquired revenue.License... ► Artikel lesen | |
PERSPECTIVE THERAPEUTICS | 3,280 | -9,39 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results | SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers... ► Artikel lesen | |
COMMUNITY HEALTH SYSTEMS | 3,080 | 0,00 % | COMMUNITY HEALTH SYSTEMS INC - 8-K, Current Report |